{"podcast":{"title":"DOC Updates","slug":"doc-updates-200053","podcast_index_feed_id":200053,"rss_url":"https://diabetescoreupdate.libsyn.com/rss","website_url":"http://diabetescoreupdate.libsyn.com","image_url":"https://static.libsyn.com/p/assets/8/b/9/4/8b94720f00784a7316c3140a3186d450/DOCU_PodcastThumbnail_3000x3000-20260616-2cie7mvhpx.png","author":"American Diabetes Association","episode_count":100,"summary":"DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles in the field of diabetes research and care, including the American Diabetes Association's three science and health journals – Diabetes, Diabetes Care, and Diabetes, Obesity, and Cardiometabolic CARE. Each episode is approximately 15 minutes long and presents 5-6 recently published articles from ADA journals and beyond. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research and information published in journals of the American Diabetes Association and beyond are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit www.diabetesjournals.org. Presented by: Neil Skolnik, M.D. , Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Clinical Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency…","last_synced_at":"2026-06-25T04:17:43.445630+00:00","page_url":"https://stenobird.com/podcast/doc-updates-200053"},"episode":{"title":"Special Edition: What's Next—Oral GLP-1 Receptor Agonists","slug":"special-edition-what-s-next-oral-glp-1-receptor-agonists","published_at":"2026-02-11T11:56:00+00:00","page_url":"https://stenobird.com/podcast/doc-updates-200053/special-edition-what-s-next-oral-glp-1-receptor-agonists","show_page_url":"https://stenobird.com/podcast/doc-updates-200053","url":"https://diabetescoreupdate.libsyn.com/special-edition-oral-glp-1-receptor-agonist","audio_url":"https://traffic.libsyn.com/secure/diabetescoreupdate/Special_Edition_-_Oral_GLP-1_RAs_February_2026.mp3?dest-id=159994","summary":"In this special series on Oral GLP-1 Receptor Agonists, Dr. Neil Skolnik will discuss the first of the GLP-1 RAs to receive FDA approval, Semaglutide. This special episode is sponsored with support from Novo Nordisk. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health W. Timothy Garvey, MD., Butterworth Professor and University Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham. Selected references : Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial . Knop, Filip K et al. The Lancet, Volume 402, Issue 10403, 705 – 719 Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity . Wharton Sean et al. N Engl J Med 2025;393:1077-1087 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes . Lincoff, A Michael, et al. N Engl J Med 2023;389:2221-2232","meta_description":"In this special series on Oral GLP-1 Receptor Agonists, Dr. Neil Skolnik will discuss the first of the GLP-1 RAs to receive FDA approval, Semaglutide. Thi…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1755,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/doc-updates-200053/episodes/special-edition-what-s-next-oral-glp-1-receptor-agonists/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/doc-updates-200053/special-edition-what-s-next-oral-glp-1-receptor-agonists.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}